Análisis
Análisis en profundidad de mercados farmacéuticos, cadenas de suministro, tecnología y regulación
#supply chain ×
Análisis
30 ago 2026•1 min de lectura
Domestic NOAC leader Rixiana faces supply strain ahead of November patent expiry
Rixiana (edoxaban) shows signs of supply pressure across all dosages as its Korean patent expires in November, prompting close monitoring of the market.
Análisis
30 ago 2026•1 min de lectura
Supply Prices of Hydrasexan Antidiarrheal Raised Effective July 1
Korean Aebot and Samjin Pharma have sharply increased the supply price of the pediatric and adult antidiarrheal Hydrasexan due to raw‑material costs and exchange‑rate shifts.